Skip to content

Ayurvedic Treatment in Alzheimers

Comparative Clinical Evaluation of Hapushadi Yapan Basti and Brahmi Ghrita in the management of Alzheimers Disesse

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/07/009171
Enrollment
90
Registered
2017-07-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Dementia (Alzheimers) Health Condition 2: G308- Other Alzheimers disease

Interventions

Intervention1: Hapushadi Yapan Basti: HYB Dose- 380 ml
Dosage form- decoction
Route of administration- Anal
Time of administration- two hours after breakfast
Duration- 1 month
Parihaar Kala- 2 months Intervention2: Brahmi Ghrita: BRAHMI GHRITA-Dose 40 gm twice daily
Route of Administration Oral
Duration of therapy- 3 months Control Intervention1: Donepazil: Dose- 10mg daily, Dosage form- Tablet
Duration of therapy- 3 months

Sponsors

Department of Kayachikitsa
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients fulfilling the criteria of possible Alzheimerâ??s disease according to NINCDS- ADRDA 2.Patients without any other probable or possible causes of Dementia 3.Patients who has done at least primary education up to class five

Exclusion criteria

Exclusion criteria: 1. Patients with any kind of kidney disorders 2. Early onset of a focal seizure suggests 3. Previous or ongoing depression 4. Early prominent gait disturbance with only mild memory loss 5. Resting tremor with stooped posture 6. When dementia occurs after a well-established diagnosis of PD 7. The early appearance of Parkinsonian features in association with fluctuating alertness, visual hallucinations, or delusional misidentification suggests 8. Chronic alcoholism 9. Vitamin B12 deficiency 10. Chronic drug intoxication. 11. Dementia with any other explainable cause

Design outcomes

Primary

MeasureTime frame
Symptomatic Improvement by Modified Mini Mental State (MMMS) testTimepoint: At Baseline, 30th day- 60th day and at the end of follow up on 90th day

Secondary

MeasureTime frame
Change in Acetyl choline esterase level, Antioxidants, inflammatory markersTimepoint: At Baseline and on 90th day

Countries

India

Contacts

Public ContactRICHA TRIPATHI

Institute of Medical Sciences, BHU

richa.23oct@gmail.com9005109368

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026